Literature DB >> 17512448

Chemotherapy for metastatic breast cancer.

Erica L Mayer1, Harold J Burstein.   

Abstract

Cytotoxic chemotherapy is a mainstay of treatment for advanced breast cancer. Treatment of metastatic (also called stage IV, advanced, or recurrent) breast cancer is not considered curative. Rather, the goals of treatment with chemotherapy are to prolong survival, alleviate or prevent tumor-related symptoms or complications, and improve quality of life. While the purpose of chemotherapy is to prevent or alleviate symptoms, chemotherapy paradoxically carries considerable toxicities that cause substantial symptoms in patients, notoriously including fatigue, nausea, vomiting, diarrhea, hair loss, mucositis, neutropenia, and neuropathy. Balancing the benefits and the side effects of chemotherapy is further complicated by the natural history of advanced breast cancer, which can be quite prolonged and typically involves multiple lines of chemotherapy, especially in patients whose tumors respond to treatment.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17512448     DOI: 10.1016/j.hoc.2007.03.001

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN: 0889-8588            Impact factor:   3.722


  14 in total

1.  Efficacy of different dosing schedules of capecitabine for metastatic breast cancer: a single-institution experience.

Authors:  Anupama Suresh; Akannsha Ganju; Evan Morgan; Marilly Palettas; Julie A Stephens; Joseph Liu; Michael Berger; Craig Vargo; Anne Noonan; Raquel Reinbolt; Mathew Cherian; Jeffrey VanDeusen; Sagar Sardesai; Robert Wesolowski; Daniel G Stover; Maryam Lustberg; Bhuvaneswari Ramaswamy; Nicole Williams
Journal:  Invest New Drugs       Date:  2020-01-14       Impact factor: 3.850

2.  Advances in the management of metastatic breast cancer: options beyond first-line chemotherapy.

Authors:  J P M Ayoub; Sh Verma; Su Verma
Journal:  Curr Oncol       Date:  2012-04       Impact factor: 3.677

3.  Factors affecting receipt of chemotherapy in women with breast cancer.

Authors:  Libby Morimoto; Jenna Coalson; Fionna Mowat; Cynthia O'Malley
Journal:  Int J Womens Health       Date:  2010-08-09

4.  A pooled analysis of gemcitabine plus docetaxel versus capecitabine plus docetaxel in metastatic breast cancer.

Authors:  Andrew D Seidman; Stephen Chan; Jin Wang; Chao Zhu; Cong Xu; Binghe Xu
Journal:  Oncologist       Date:  2014-04-04

5.  Higher rate of skin rash in a phase II trial with weekly nanoparticle albumin-bound paclitaxel and cisplatin combination in Chinese breast cancer patients.

Authors:  Li Chen Tang; Bi Yun Wang; Si Sun; Jian Zhang; Zhen Jia; Yun Hua Lu; Geng Hong Di; Zhi Ming Shao; Xi Chun Hu
Journal:  BMC Cancer       Date:  2013-05-09       Impact factor: 4.430

6.  Sequential Metastatic Breast Cancer Chemotherapy: Should the Median be the Message?

Authors:  Su Yon Jung; Margaret Rosenzweig
Journal:  Front Public Health       Date:  2013-11-11

7.  Troglitazone reverses the multiple drug resistance phenotype in cancer cells.

Authors:  Gerald F Davies; Bernhard H J Juurlink; Troy A A Harkness
Journal:  Drug Des Devel Ther       Date:  2009-09-21       Impact factor: 4.162

8.  Nanoparticle albumin bound Paclitaxel in the treatment of human cancer: nanodelivery reaches prime-time?

Authors:  Iole Cucinotto; Lucia Fiorillo; Simona Gualtieri; Mariamena Arbitrio; Domenico Ciliberto; Nicoletta Staropoli; Anna Grimaldi; Amalia Luce; Pierfrancesco Tassone; Michele Caraglia; Pierosandro Tagliaferri
Journal:  J Drug Deliv       Date:  2013-05-02

Review 9.  Impact of skeletal complications on patients' quality of life, mobility, and functional independence.

Authors:  Luis Costa; Xavier Badia; Edward Chow; Allan Lipton; Andrew Wardley
Journal:  Support Care Cancer       Date:  2008-04-08       Impact factor: 3.359

10.  Phase I and II Study of Gemcitabine and Vinorelbine in Heavily Pretreated Patients with Metastatic Breast Cancer and Review of the Literature.

Authors:  Pamela Abdayem; Marwan Ghosn; Vicente Valero; Ronald Walters; Banu Arun; James L Murray; Richard Theriault; Debbie Frye; Nuhad K Ibrahim
Journal:  J Cancer       Date:  2014-03-29       Impact factor: 4.207

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.